Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers
Status:
COMPLETED
Trial end date:
2024-02-19
Target enrollment:
Participant gender:
Summary
Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus